An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India
MetadataShow full item record
© 2015 Kanungo et al. The bivalent killed oral cholera vaccine (OCV) provides 65% cumulative protection over five years. It remains unknown whether a boosting regimen can maintain protection in previously immunized populations. This study examines the immunogenicity and safety of an OCV regimen given five years following initial dosing. An open label controlled trial was conducted in 426 healthy Indian participants previously enrolled in a large efficacy trial. To assess whether an OCV regimen given after five years can elicit an antibody response equal to that of a primary series, we compared vibriocidal antibody titers in previously immunized participants receiving a two dose booster regimen to participants receiving a primary two dose immunization series. Among participants receiving a two dose primary series of OCV (n = 186), 69% (95% CI 62%-76%) seroconverted. In the intervention arm (n = 184), 66% (95% CI 59%-73%) seroconverted following a two dose boosting schedule given five years following the initial series. Following a single boosting dose, 71% (95% CI 64%-77%) seroconverted. Children demonstrated 79% (95% CI 69%-86%) and 82% (95% CI 73%-88%) seroconversion after primary and boosting regimens, respectively. Administration of an OCV boosting regimen elicits an immune response similar to those receiving a primary series in endemic areas. Though a single boosting dose induces a strong immune response, further investigations are needed to measure if these findings translate to clinical protection.
Showing items related by title, author, creator and subject.
Flexibility of Oral Cholera Vaccine Dosing—A Randomized Controlled Trial Measuring Immune Responses Following Alternative Vaccination Schedules in a Cholera Hyper-Endemic ZoneKanungo, S.; Desai, S.; Nandy, R.; Bhattacharya, M.; Kim, D.; Sinha, A.; Mahapatra, T.; Yang, J.; Lopez, A.; Manna, B.; Bannerjee, B.; Ali, Mohammed; Dhingra, M.; Chandra, A.; Clemens, J.; Sur, D.; Wierzba, T. (2015)© 2015 Kanungo et al. Background: A bivalent killed whole cell oral cholera vaccine has been found to be safe and efficacious for five years in the cholera endemic setting of Kolkata, India, when given in a two dose ...
Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trialQadri, F.; Ali, Mohammed; Lynch, J.; Chowdhury, F.; Khan, A.; Wierzba, T.; Excler, J.; Saha, A.; Islam, M.; Begum, Y.; Bhuiyan, T.; Khanam, F.; Chowdhury, M.; Khan, I.; Kabir, A.; Riaz, B.; Akter, A.; Khan, A.; Asaduzzaman, M.; Kim, D.; Siddik, A.; Saha, N.; Cravioto, A.; Singh, A.; Clemens, J. (2018)© 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: A single-dose regimen of inactivated whole-cell oral cholera vaccine (OCV) is attractive because it ...
Modelling the co-occurence of Streptococcus pneumoniae with other bacterial and viral pathogens in the upper respiratory tractJacoby, P.; Watson, K.; Bowman, J.; Taylor, A.; Riley, T.; Smith, D.; Lehmann, Deborah (2007)Go to ScienceDirect® Home Skip Main Navigation Links Brought to you by: The University of Western Australia Library Login: + Register Athens/Institution Login Not Registered? - User Name: Password: ...